• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

A Phase 3 Trial of Resmetirom in NASH with Liver Fibrosis. Reply.

作者信息

Harrison Stephen A, Taub Rebecca

机构信息

Pinnacle Clinical Research, San Antonio, TX

Madrigal Pharmaceuticals, West Conshohocken, PA.

出版信息

N Engl J Med. 2024 May 2;390(17):1632-1633. doi: 10.1056/NEJMc2402905.

DOI:10.1056/NEJMc2402905
PMID:38692302
Abstract
摘要

相似文献

1
A Phase 3 Trial of Resmetirom in NASH with Liver Fibrosis. Reply.一项用于治疗非酒精性脂肪性肝炎伴肝纤维化的resmetirom 3期试验。回复。
N Engl J Med. 2024 May 2;390(17):1632-1633. doi: 10.1056/NEJMc2402905.
2
A Phase 3, Randomized, Controlled Trial of Resmetirom in NASH with Liver Fibrosis.一项评估 Resmetirom 治疗伴有肝纤维化的 NASH 的 3 期随机对照试验。
N Engl J Med. 2024 Feb 8;390(6):497-509. doi: 10.1056/NEJMoa2309000.
3
Resmetirom (MGL-3196) for the treatment of non-alcoholic steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial.Resmetirom（MGL-3196）治疗非酒精性脂肪性肝炎：一项多中心、随机、双盲、安慰剂对照的 2 期临床试验。
Lancet. 2019 Nov 30;394(10213):2012-2024. doi: 10.1016/S0140-6736(19)32517-6. Epub 2019 Nov 11.
4
A Phase 3 Trial of Resmetirom in NASH with Liver Fibrosis.一项评估resmetirom治疗非酒精性脂肪性肝炎伴肝纤维化的3期试验。
N Engl J Med. 2024 May 2;390(17):1632. doi: 10.1056/NEJMc2402905.
5
Effects of Resmetirom on Noninvasive Endpoints in a 36-Week Phase 2 Active Treatment Extension Study in Patients With NASH.在一项为期 36 周的 NASH 患者 2 期活性治疗延伸研究中，Resmetirom 对非侵入性终点的影响。
Hepatol Commun. 2021 Jan 4;5(4):573-588. doi: 10.1002/hep4.1657. eCollection 2021 Apr.
6
Resmetirom: First Approval.雷美替胺：首次获批
Drugs. 2024 Jun;84(6):729-735. doi: 10.1007/s40265-024-02045-0. Epub 2024 May 21.
7
A new mechanism of thyroid hormone receptor β agonists ameliorating nonalcoholic steatohepatitis by inhibiting intestinal lipid absorption via remodeling bile acid profiles.甲状腺激素受体 β 激动剂通过重塑胆汁酸谱抑制肠道脂质吸收改善非酒精性脂肪性肝炎的新机制。
Acta Pharmacol Sin. 2024 Oct;45(10):2134-2148. doi: 10.1038/s41401-024-01303-x. Epub 2024 May 24.
8
Role of Resmetirom, a Liver-Directed, Thyroid Hormone Receptor Beta-Selective Agonist, in Managing Nonalcoholic Steatohepatitis: A Systematic Review and Meta-Analysis.Resmetirom 作为一种肝脏靶向、甲状腺激素受体β选择性激动剂，在治疗非酒精性脂肪性肝炎中的作用：系统评价和荟萃分析。
Endocr Pract. 2024 Jul;30(7):631-638. doi: 10.1016/j.eprac.2024.04.016. Epub 2024 May 1.
9
Thyromimetics as emerging therapeutic agents for nonalcoholic steatohepatitis: rationale for the development of resmetirom (MGL-3196).甲状腺模拟物作为非酒精性脂肪性肝炎的新型治疗药物：resmetirom（MGL-3196）的研发原理
Expert Opin Investig Drugs. 2020 Feb;29(2):99-101. doi: 10.1080/13543784.2020.1708899. Epub 2019 Dec 25.
10
Insights into the results of Resmetirom trials: Can a thyroid hormone receptor agonist be the holy grail of MASH therapy?Resmetirom试验结果洞察：甲状腺激素受体激动剂能否成为非酒精性脂肪性肝炎治疗的圣杯？
Pharmacol Ther. 2025 Apr;268:108811. doi: 10.1016/j.pharmthera.2025.108811. Epub 2025 Feb 10.

引用本文的文献

1
Metabolic-Associated Steatotic Liver Disease: From Molecular Mechanisms to Novel Therapies.代谢相关脂肪性肝病：从分子机制到新型疗法
Int J Hepatol. 2025 Jun 23;2025:5580454. doi: 10.1155/ijh/5580454. eCollection 2025.
2
Combination Therapy of Half-Dose Resmetirom and Metformin Attenuates Metabolic Dysfunction-Associated Steatohepatitis Through Improving Cholesterol Metabolism and Inflammation.半剂量瑞美鲁肽与二甲双胍联合治疗通过改善胆固醇代谢和炎症减轻代谢功能障碍相关脂肪性肝炎
Biomedicines. 2025 May 27;13(6):1315. doi: 10.3390/biomedicines13061315.
3
Hepatic AKAP1 deficiency exacerbates diet-induced MASLD by enhancing GPAT1-mediated lysophosphatidic acid synthesis.
肝脏AKAP1缺乏通过增强GPAT1介导的溶血磷脂酸合成加剧饮食诱导的代谢相关脂肪性肝病。
Nat Commun. 2025 May 8;16(1):4286. doi: 10.1038/s41467-025-58790-7.
4
Single-cell landscape of peripheral immune cells in MASLD/MASH.代谢相关脂肪性肝病/非酒精性脂肪性肝炎中外周免疫细胞的单细胞图谱
Hepatol Commun. 2025 Apr 21;9(5). doi: 10.1097/HC9.0000000000000643. eCollection 2025 May 1.
5
Ramadan Fasting and Complications of Metabolic Dysfunction-Associated Steatotic Liver Disease: Impacts on Liver Cirrhosis and Heart Failure.斋月禁食与代谢功能障碍相关脂肪性肝病的并发症：对肝硬化和心力衰竭的影响。
J Clin Med. 2025 Mar 9;14(6):1841. doi: 10.3390/jcm14061841.
6
Ramadan Fasting in Individuals with Metabolic Dysfunction-Associated Steatotic Liver Disease, Liver Transplant, and Bariatric Surgery: A Narrative Review.代谢功能障碍相关脂肪性肝病、肝移植和减肥手术患者的斋月禁食：一项叙述性综述
J Clin Med. 2024 Jul 2;13(13):3893. doi: 10.3390/jcm13133893.